Search

Your search keyword '"Nahass, Ronald G."' showing total 17 results
Start Over Author "Nahass, Ronald G." Publication Year Range Last 3 years
17 results on '"Nahass, Ronald G."'

1. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

Author

Yuen, Man-Fung, Fung, Scott, Ma, Xiaoli, Nguyen, Tuan T., Hassanein, Tarek, Hann, Hie-Won, Elkhashab, Magdy, Nahass, Ronald G., Park, James S., Jacobson, Ira M., Ayoub, Walid S., Han, Steven-Huy, Gane, Edward J., Zomorodi, Katie, Yan, Ran, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Weilert, Frank, Ramji, Alnoor, Bennett, Michael, Ravendhran, Natarajan, Chan, Sing, Dieterich, Douglas T., Kwo, Paul Yien, Schiff, Eugene R., Bae, Ho S., Lalezari, Jacob, Agarwal, Kosh, and Sulkowski, Mark S.

Published
2024
Full Text
View/download PDF

2. WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment

Author

Yuen, Man-Fung, primary, Heo, Jeong, additional, Nahass, Ronald G., additional, Wong, Grace Lai-Hung, additional, Burda, Tatiana, additional, Bhamidimarri, Kalyan Ram, additional, Hu, Tsung-Hui, additional, Nguyen, Tuan T., additional, Lim, Young-Suk, additional, Chen, Chi-Yi, additional, Gordon, Stuart C., additional, Holmes, Jacinta, additional, Chuang, Wan-Long, additional, Kohli, Anita, additional, Alkhouri, Naim, additional, Gray, Kevin, additional, Thi, Emily P., additional, Medvedeva, Elina, additional, Eley, Timothy, additional, Ganchua, Sharie C., additional, Iott, Christina, additional, Eill, Elizabeth, additional, Espiritu, Christine L., additional, Anderson, Mark, additional, Fortney, Tiffany, additional, Cloherty, Gavin, additional, and Sims, Karen D., additional

Published
2024
Full Text
View/download PDF

3. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

Author

Sulkowski, Mark S., Agarwal, Kosh, Ma, Xiaoli, Nguyen, Tuan T., Schiff, Eugene R., Hann, Hie-Won L., Dieterich, Douglas T., Nahass, Ronald G., Park, James S., Chan, Sing, Han, Steven-Huy B., Gane, Edward J., Bennett, Michael, Alves, Katia, Evanchik, Marc, Yan, Ran, Huang, Qi, Lopatin, Uri, Colonno, Richard, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Jacobson, Ira M., Ayoub, Walid S., Weilert, Frank, Ravendhran, Natarajan, Ramji, Alnoor, Kwo, Paul Yien, Elkhashab, Magdy, Hassanein, Tarek, Bae, Ho S., Lalezari, Jacob P., Fung, Scott K., and Yuen, Man-Fung

Published
2022
Full Text
View/download PDF

4. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

Author

Yuen, Man-Fung, Agarwal, Kosh, Ma, Xiaoli, Nguyen, Tuan T., Schiff, Eugene R., Hann, Hie-Won L., Dieterich, Douglas T., Nahass, Ronald G., Park, James S., Chan, Sing, Han, Steven-Huy B., Gane, Edward J., Bennett, Michael, Alves, Katia, Evanchik, Marc, Yan, Ran, Huang, Qi, Lopatin, Uri, Colonno, Richard, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Jacobson, Ira M., Ayoub, Walid S., Weilert, Frank, Ravendhran, Natarajan, Ramji, Alnoor, Kwo, Paul Yien, Elkhashab, Magdy, Hassanein, Tarek, Bae, Ho S., Lalezari, Jacob P., Fung, Scott K., and Sulkowski, Mark S.

Published
2022
Full Text
View/download PDF

6. Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection

Author

Yuen, Man-Fung, primary, Heo, Jeong, additional, Nahass, Ronald G, additional, Wong, Grace Lai-Hung, additional, Burda, Tatiana, additional, Bhamidimarri, Kalyan Ram, additional, Hu, Tsung-Hui, additional, Nguyen, Tuan, additional, Lim, Young-Suk, additional, Chen, Chi-Yi, additional, Gordon, Stuart C, additional, Holmes, Jacinta, additional, Chuang, Wan-Long, additional, Kohli, Anita, additional, Alkhouri, Naim, additional, Gray, Kevin, additional, Thi, Emily P., additional, Medvedeva, Elina, additional, Eley, Timothy, additional, and Sims, Karen, additional

Published
2023
Full Text
View/download PDF

8. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

Author

Janssen, Harry L A, primary, Hou, Jinlin, additional, Asselah, Tarik, additional, Chan, Henry L Y, additional, Zoulim, Fabien, additional, Tanaka, Yasuhito, additional, Janczewska, Ewa, additional, Nahass, Ronald G, additional, Bourgeois, Stefan, additional, Buti, Maria, additional, Lampertico, Pietro, additional, Lenz, Oliver, additional, Verbinnen, Thierry, additional, Vandenbossche, Joris, additional, Talloen, Willem, additional, Kalmeijer, Ronald, additional, Beumont, Maria, additional, Biermer, Michael, additional, and Shukla, Umesh, additional

Published
2023
Full Text
View/download PDF

9. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B

Author

Sulkowski, Mark S, primary, Fung, Scott K, additional, Ma, Xiaoli, additional, Nguyen, Tuan T, additional, Schiff, Eugene R., additional, Hann, Hie-Won L, additional, Dieterich, Douglas T, additional, Nahass, Ronald G, additional, Park, James S, additional, Chan, Sing, additional, Han, Steven-Huy B, additional, Gane, Edward J, additional, Bennett, Michael, additional, Yan, Ran, additional, Liu, Jieming, additional, Ma, Julie, additional, Knox, Steven J, additional, Stamm, Luisa M, additional, Bonacini, Maurizio, additional, Jacobson, Ira M, additional, Ayoub, Walid S, additional, Weilert, Frank, additional, Ravendhran, Natarajan, additional, Ramji, Alnoor, additional, Kwo, Paul Yien, additional, Elkhashab, Magdy, additional, Hassanein, Tarek, additional, Bae, Ho S, additional, Lalezari, Jacob P, additional, Agarwal, Kosh, additional, and Yuen, Man-Fung, additional

Published
2022
Full Text
View/download PDF

11. Successful Treatment of Cutibacterium acnes Prosthetic Joint Infection With Single-Stage Exchange and Oral Antibiotics.

Author

Kohm, Kevin, Seneca, Kathleen, Smith, Krystle, Heinemann, Danielle, and Nahass, Ronald G

Subjects
CUTIBACTERIUM acnes, JOINT infections, ARTIFICIAL joints, TREATMENT effectiveness, ANTIBIOTICS
Abstract

Interest has grown in less invasive surgical treatment and early use of oral antibiotics in the treatment of Cutibacterium acnes prosthetic joint infection. We report a series of patients who were successfully treated with single-stage exchange and an all-oral course of rifampin and linezolid. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis.

Author

Filippo, Savanna San, Crovetto, Brynna, Bucek, John, Nahass, Ronald G, Milano, Marc, and Brunetti, Luigi

Abstract

Background Bamlanivimab and casirivimab/imdevimab are monoclonal antibody (mAb) treatments used for mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. To date, there are few data summarizing real-world evidence comparing the 2 mAbs. Additionally, there are insufficient data to guide administration timing relative to symptom onset. The purpose of this study was to evaluate 30-day failure rates for each agent and to identify the relationship between symptom onset and efficacy. Methods We performed a retrospective cohort study of a 6-month period at a large community medical center. Consecutive outpatients diagnosed with COVID-19 disease by nasopharyngeal (NP) polymerase chain reaction (PCR) testing received either bamlanivimab 700 mg or casirivimab/imdevimab 1200 mg/1200 mg. Each patient was followed for a total of 30 days. Three independent, blinded physicians performed adjudication for revisit reasons. The primary outcome was therapy-related failure, defined as COVID-19-related hospital admission within 30 days of infusion. Multivariable logistic regression was performed to adjust for confounders that may have influenced hospital admission in either group. Results During the period from November 2020 to May 2021, 183 patients were treated with bamlanivimab and 270 with casirivimab/imdevimab. The mean age was ~67 years and body mass index 30 kg/m2. Thirty-day admission for therapy-related failure rates were 4.8% and 13.7% for casirivimab/imdevimab and bamlanivimab, respectively (P  = .001). No significant differences were found between early (<3 days of symptom onset) and late administration of either mAb. Conclusions There was a higher failure rate with bamlanivimab vs casirivimab/imdevimab. No difference in efficacy was found between early vs late administration of either mAb. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

17. LBP-38 - Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection

Author

Yuen, Man-Fung, Heo, Jeong, Nahass, Ronald G, Wong, Grace Lai-Hung, Burda, Tatiana, Bhamidimarri, Kalyan Ram, Hu, Tsung-Hui, Nguyen, Tuan, Lim, Young-Suk, Chen, Chi-Yi, Gordon, Stuart C, Holmes, Jacinta, Chuang, Wan-Long, Kohli, Anita, Alkhouri, Naim, Gray, Kevin, Thi, Emily P., Medvedeva, Elina, Eley, Timothy, and Sims, Karen

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results